3 ASX 300 healthcare stocks 'well positioned to outperform'

Wilsons thinks the healthcare sector could be about to outperform the broader market.

| More on:
Shot of a mature scientists working on a laptop in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The performance of the healthcare sector has been relatively underwhelming in recent times.

While this is disappointing, the team at Wilsons believes that things could change in the near future. This could make it a great time for investors to ensure that their investment portfolios are positioned to take advantage of this. The broker said:

After ~2 years of lacklustre performance at the index level, the outlook for the ASX 300 healthcare sector is highly attractive. The sector is well positioned to outperform over the medium-term given its earnings trajectory is considerably stronger than the broader market while the sector's valuation is also at highly attractive levels.

But which ASX 300 healthcare stocks could be worth considering? Let's take a look at three that its analysts are feeling bullish on and have in their Focus Portfolio. They are as follows:


The first ASX 300 healthcare stock that Wilsons has in its Focus Portfolio is biotechnology giant CSL.

The broker is currently overweight on CSL's shares. Though, it has admittedly been more positive in the past. It explains:

On balance, our increasingly constructive view on the outlook for Behring's earnings recovery warrants our modest overweight exposure to CSL, albeit our level of conviction is tempered to an extent by the subdued outlooks of Vifor and Seqirus and the somewhat uncompelling level of R&D pipeline upside over the medium-term. Valuation wise, CSL is broadly in line with our 'fair value' range, balancing the fact that a) CSL trades on forward PE of ~27x which is below its 5-year average, and b) CSL is somewhat 'expensive' relative to global biopharma peers. To become more constructive on CSL, we are looking for a) developments in the R&D pipeline, b) demonstrated progress on Behring's margin recovery, and/or c) a meaningful turnaround in the performance of Vifor and Seqirus.

ResMed Inc. (ASX: RMD)

Another ASX 300 healthcare stock that features is sleep disorder treatment ResMed.

Its analysts highlight that its shares trade at a sharp discount to historical multiples. And given how weight loss drugs concerns are starting to ease, it feels a re-rating could take place soon. Wilsons commented:

Notwithstanding RMD's solid earnings-driven share price recovery, the company remains on an excessive valuation discount at a 12-month forward PE multiple of ~23x, which is a ~30% discount to both the 5-year average and RMD's 'pre GLP-1' level. We expect RMD's valuation to re-rate higher as GLP-1 concerns progressively abate and the market shifts its focus to the strong fundamental outlook of the business.

Telix Pharmaceuticals Ltd (ASX: TLX)

Finally, this high-flying radiopharmaceuticals company could be worth a closer look.

Wilsons is very positive on the ASX 300 healthcare stock's Illuccix product and extensive pipeline. It said:

A key appeal of TLX is that its extensive pipeline offers significant valuation and earnings upside potential, which is complimented by the robust cash flows already generated by Illuccix. Following recent pipeline updates on TLX591 (SELECT rPFS data) and Zircaix (BLA submission) there is still a cavalcade of catalysts that represent 'de-risking' points in TLX's valuation and will drive the share price over the next 12 months.

Motley Fool contributor James Mickleboro has positions in CSL, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Telix Pharmaceuticals share price sinks on unexpected Nasdaq news

ASX 200 investors are bidding down the Telix Pharmaceuticals share price today. But why?

Read more »

Health workers shake hands and congratulate each other on good news.
Healthcare Shares

This ASX 200 healthcare stock is up 48% in a year, but one director is still buying!

A director of this ASX 200 healthcare company has just lifted his personal stake by 50%.

Read more »

A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts
Healthcare Shares

Why this broker just upgraded Telix shares to a buy rating

Bell Potter thinks a recent pullback has created a buying opportunity.

Read more »

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
Healthcare Shares

Sigma share price dives 6% on Chemist Warehouse merger hurdle

The proposed merger faces ACCC concerns.

Read more »

A person wrapped in warm clothing with head, eyes and face covered by a hat, glasses and a scarf is coated in a layer of snow and ice. representing Strike Energy's trading halt today
Healthcare Shares

Why is the Telix Pharmaceuticals share price frozen today?

Telix Pharmaceuticals shares won’t be moving today.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

CSL shares can 'absolutely' head to $500: ASX expert

This expert reckons it's foolish to bet against CSL...

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX biotech shares that could be the next Telix Pharmaceuticals

These ASX biotech shares could become the next Telix Pharmaceuticals. But how?

Read more »

Businessman working on street in New York. Dressing in blue suit, a young guy with beard, sitting outside office building, looking down, reading, typing on laptop computer.
Healthcare Shares

Telix Pharmaceuticals share price jumps to record high on Nasdaq IPO launch

This radiopharmaceuticals company is expecting to pull in US$200m from the move.

Read more »